Investor Presentation for the quarter ended June 30, 2026.

Investor Presentation - Q1FY27 - Consolidated revenue grew 21% y-y to ₹110.2 cr; standalone revenue ₹86.1 cr +21% y-y - Domestic business revenue up 17% y-y; exports rebounded 29% y-y - Margins impacted by raw material price rise and expenses from new Panchla and Amta facilities - Amta facility commercial supplies started; Panchla cell culture lines commissioning expected end Q2FY27 - PAT negative ₹1.4 cr consolidated; cash PAT grew 18% y-y to ₹25.6 cr - Management confident of sustained demand and growth from expanded product portfolio and capacities - Focus on expanding exports to ~120 countries over next 5-10 years - State-of-the-art automated manufacturing with ISO certifications supports quality and scalability